Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | PRF1 | P14222 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788146 | 0.85 | CYP2A6 (0.56) | ALDH1A1MAPTHSD17B10CYP2A6KDM4E | |
| SCHEMBL5544081 | 0.81 | ALDH1A1 (0.44) | ALDH1A1MAPTHSD17B10KDM4ERXFP1 | |
| SCHEMBL34459993 | 0.81 | ALDH1A1 (0.44) | ALDH1A1MAPTHSD17B10KDM4ERXFP1 | |
| SCHEMBL28633959 | 0.81 | ESR1 (0.49) | ALDH1A1MAPTHSD17B10RXFP1TSHR | |
| SCHEMBL5544027 | 0.80 | ALDH1A1 (0.69) | ALDH1A1MAPTHSD17B10CYP2A6KDM4E | |
| SCHEMBL14599487 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTHSD17B10KDM4EPRF1 | |
| SCHEMBL28462880 | 0.79 | ALDH1A1 (0.68) | ALDH1A1MAPTHSD17B10KDM4ERXFP1 | |
| SCHEMBL8056400 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTHSD17B10KDM4ERXFP1 | |
| SCHEMBL29768596 | 0.79 | TSHR (0.46) | ALDH1A1MAPTHSD17B10KDM4ERXFP1 | |
| SCHEMBL5542992 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTHSD17B10KDM4EPRF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101133056-B | Antitumor compounds | NAT HEALTH RESEARCH INSTITUTES | 2010-12-01 | — | — | CN | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| CN-101133056-A | Antitumor compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2008-02-27 | — | — | CN | disclosed |
| EP-1838711-A2 | ANTI-TUMOR COMPOUNDS | National Health Research Institutes (TW) | 2007-10-03 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2006074041-A2 | ANTI-TUMOR COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148801-A1 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-06 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885MAPT 4117/4885HSD17B10 467/4885 |
| US-20060148801-A1 | Anti-tumor compounds | TUBB1, TUBB3, TUBB | ALDH1A1 2627/4885MAPT 47/4885HSD17B10 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.